Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
eNq1mF1v2jAUhu/5FVEudkcChRTYEqqNtRtSqzEK2rQbZJJDMQt26g8++uvnELrC5KirwZeJk/cc+xw/fuXwarNMnRUwjimJ3LpXcx0gMU0weYjc8eim2navupVwgVbo4LOWV/PqF64Tp4jzyM1HvSkgwr2fd7efQf0PzO1WnJBOFxCLo++kwKn3FfH5Hcryb5xwRXHiLEHMaRK5mRS7t07IBVNZdNeU/eYZiiH0928ORxeT5uH70M/F/kNVcmC3iDxoRYEYacaSMSCihwQ8ULYtybdhpI35EDiVLIYBEvMBoyucQKINMUMpB6Mgs3VyD2yVgsiDaMX9RbzkRuJogTZDeOzrk/6oRntiI6q1ar3VCi4um5eddqMZGIViB0ulr4KahB9P6o2g02oGPhB/uaVP2yUY1mZAmUCppapg3jtuLEtxGDy+Wv0E8yxFW2/BM9OlQgypYWBq+9ubSD6DEVNAStWa/aNPZJr6b8x6vMeFpYxzGvWoJKKEGjdD04XoUSJgU15RM9CJzb4XMfDzyT5Roof8QE5THJsiTUFHAhfjYb+caOeEwSfEYczs0eAHJgld8/NT5rCqlrLPdqDUimYsqU8uOu3LehAYb6JfqoVKTphryWgGvuIP5qdgpU9m9FSgqK7USz335NnacedzaIxSKHE6VUO2qD58NmbWOt3eLioGtKJfrkem7fFdAtve7x610jiJ/hbWDLw2aK6a8bXEi20bZZNGLWh3Gs13aJl9eLbQkaFdLkStuGXJ9IyZC5Hx976/Xq+9OeJVjtR6ejNWfgZcaad+jukr4L5U056ht2IACkNUwNZS6tPiFH1bGU037msW4VTbu/9/b6+1MQSTcEItCsZbI3H/+vxwf/G81tIeHCHGXpidP0UCU2LLN8mpVvG040TVldwwBYhvsxkuuWAp7cvQLy53upXQzy92upU/5DYBPQ==
85cMngvKhWy5gNDS
